On September 4, 2024, Harpreet Grewal, a Director at Penumbra Inc (PEN, Financial), sold 782 shares of the company, according to the SEC Filing. Following this transaction, the insider now owns 8,863 shares of Penumbra Inc.
Penumbra Inc, based in Alameda, California, is a healthcare company focused on developing innovative medical devices. The company specializes in products designed to address challenging medical conditions in markets such as neuro and peripheral vascular conditions.
Over the past year, Harpreet Grewal has sold a total of 1,122 shares of Penumbra Inc and has not made any purchases of the stock. This recent transaction is part of a broader trend observed within the company, where there have been 26 insider sells and no insider buys over the past year.
Shares of Penumbra Inc were trading at $204.11 on the day of the transaction. The company has a market cap of approximately $7.93 billion. The price-earnings ratio of Penumbra Inc stands at 595.74, significantly higher than the industry median of 27.51 and above the company's historical median.
The GF Value of Penumbra Inc is estimated at $295.90, suggesting that the stock is significantly undervalued with a price-to-GF-Value ratio of 0.69.
The GF Value is calculated considering historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sale might be of interest to investors tracking insider behaviors and evaluating the valuation metrics and financial health of Penumbra Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
